Simultaneous Determination of Nirmatrelvir and Ritonavir in Human Plasma by HPLC-MS/MS

Simultaneous Determination of Nirmatrelvir and Ritonavir in Human Plasma by HPLC-MS/MS

Introduction. SARS-CoV-2 (severe acute respiratory syndrome-related coronavirus 2) is expected to remain a persistent global threat. Therefore, development of coronavirus disease 2019 (COVID-19) drugs is the most urgent global issue. Nirmatrelvir and ritonavir combination is an oral antiviral drug c...

Full description

Saved in:
Bibliographic Details
Main Authors: T. N. Komarov, P. K. Karnakova, O. A. Archakova, D. S. Shchelgacheva, N. S. Bagaeva, I. E. Shohin, K. Ya. Zaslavskaya, P. A. Bely
Format: Article
Language:Russian
Published: LLC Center of Pharmaceutical Analytics (LLC «CPHA») 2023-05-01
Series:Разработка и регистрация лекарственных средств
Subjects:
nirmatrelvir
ritonavir
covid-19
plasma
hplc-ms/ms
validation
pharmacokinetics
Online Access:https://www.pharmjournal.ru/jour/article/view/1493
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.pharmjournal.ru/jour/article/view/1493

Similar Items